In this context, it is recommended for future studies to verify the pathological association by combining AD biomarkers, such as amyloid PET or plasma phosphorylated tau 217 (pTau-217) [38,39], with a longitudinal study design, such as half-year evaluations, to clarify the predictive value and clinical application potential of the Greek MBI-C in dementia conversion. Here, MAPT is linked to Alzheimer disease.